GOOD READING
Heat Biologics Inc. - Get News & Ratings Daily
Enter your email address below to get the latest news and analysts' ratings for Heat Biologics Inc. with our FREE daily email newsletter:
.
Recent Stories
First Solar (FSLR) Updates FY18 Earnings Guidance
TD Securities Boosts Whitecap Resources (WCP) Price Target to C$13.00
Precision Drilling (PD) PT Lowered to C$5.50
Kinder Morgan Canada (KML) PT Lowered to C$24.00 at Royal Bank Of Canada
Scotiabank Reiterates “C$18.00” Price Target for Cascades (CAS)
Whitecap Resources (WCP) Given a C$12.50 Price Target at CIBC
Uranium Participation (U) PT Raised to C$4.50 at TD Securities
Morgan Stanley Cuts Lundin Mining (LUN) Price Target to C$6.10
Husky Energy (HSE) Given a C$17.00 Price Target by BMO Capital Markets Analysts
Uranium Participation (U) Stock Rating Upgraded by Scotiabank
Husky Energy (HSE) PT Raised to C$20.50 at GMP Securities
J P Morgan Chase & Co Raises TransCanada (TRP) Price Target to C$76.00
TD Securities Trims Kinder Morgan Canada (KML) Target Price to C$24.00
Dollarama (DOL) PT Raised to C$165.00 at Raymond James Financial
Whitecap Resources (WCP) Price Target Increased to C$13.00 by Analysts at BMO Capital Markets
Desjardins Boosts NAPEC (NPC) Price Target to C$2.25
Zacks: Analysts Expect Petroquest Energy Inc (PQ) Will Announce Quarterly Sales of $29.55 Million
Tenaris S.A. (TS) Expected to Post Quarterly Sales of $1.49 Billion
Zacks: Brokerages Anticipate Kemper Corporation (KMPR) Will Announce Quarterly Sales of $667.10 Million
Head to Head Analysis: ARMOUR Residential REIT (ARR) and BRT Realty Trust (BRT)
Zacks: Analysts Set $8.42 Price Target for Heat Biologics, Inc. (HTBX)
December 5th, 2017 • 0 comments • Filed Under • by ABMN Staff
in
Share
Heat Biologics, Inc. (NASDAQ:HTBX) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price objective of $8.42 for the company and are forecasting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Heat Biologics an industry rank of 104 out of 265 based on the ratings given to related companies.
Get Heat Biologics Inc. alerts:
Separately, Griffin Securities began coverage on Heat Biologics in a research note on Tuesday, September 12th. They issued a “buy” rating and a $2.25 target price for the company.
Shares of Heat Biologics (NASDAQ:HTBX) traded down $0.03 during mid-day trading on Tuesday, reaching $0.43. The company had a trading volume of 423,000 shares, compared to its average volume of 605,148. Heat Biologics has a one year low of $0.41 and a one year high of $1.44.
Heat Biologics (NASDAQ:HTBX) last issued its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.03. The company had revenue of $0.47 million during the quarter, compared to analyst estimates of $0.50 million. Heat Biologics had a negative return on equity of 149.69% and a negative net margin of 1,184.92%. analysts forecast that Heat Biologics will post -0.38 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Heat Biologics stock. KCG Holdings Inc. raised its stake in shares of Heat Biologics, Inc. (NASDAQ:HTBX) by 35.3% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 175,769 shares of the biopharmaceutical company’s stock after buying an additional 45,831 shares during the period. KCG Holdings Inc. owned about 0.52% of Heat Biologics worth $156,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Get a free copy of the Zacks research report on Heat Biologics (HTBX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
AI
